menu
    • menu
    [{"orgOrder":0,"company":"Walking Fish Therapeutics","sponsor":"Emerson Collective","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Engineered B-cells Therapeutics","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Walking Fish Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Walking Fish Therapeutics \/ Emerson Collective","highestDevelopmentStatusID":"4","companyTruncated":"Walking Fish Therapeutics \/ Emerson Collective"},{"orgOrder":0,"company":"Walking Fish Therapeutics","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"B Cell-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Walking Fish Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Walking Fish Therapeutics \/ Walking Fish Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Walking Fish Therapeutics \/ Walking Fish Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Walking Fish Therapeutics

    Menu

    Walking Fish Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Walking Fish Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Walking Fish Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B Cell-based Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Inno...

                            Details : Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : B Cell-based Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Walking Fish Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Walking Fish Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered B-cells Therapeutics

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Emerson Collective

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell ...

                            Details : Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer which includes its lead product WFT-1.

                            Brand Name : WFT-1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 13, 2021

                            Lead Product(s) : Engineered B-cells Therapeutics

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Emerson Collective

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth